ArticlePloS one2017
Characterization and formulation into solid dosage forms of a novel bacteriophage lytic against Klebsiella oxytoca.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- Spot-on phage therapy: stable formulations, smarter dosing for topical phage application.Frontiers in cellular and infection microbiology · 2026Review
- Weberviruses are gut-associated phages that infect Klebsiella spp.FEMS microbiology ecology · 2025Article
- A Klebsiella-phage cocktail to broaden the host range and delay bacteriophage resistance both in vitro and in vivo.NPJ biofilms and microbiomes · 2024Article
- Article
- Effects ofViruses · 2022Article
- Manufacturing Bacteriophages (Part 2 of 2): Formulation, Analytics and Quality Control Considerations.Pharmaceuticals (Basel, Switzerland) · 2021Review
- The Age of Phage: Friend or Foe in the New Dawn of Therapeutic and Biocontrol Applications?Pharmaceuticals (Basel, Switzerland) · 2021Review
- Novel Drexlerviridae bacteriophage KMI8 with specific lytic activity against Klebsiella michiganensis and its biofilms.PloS one · 2021Article
- Characteristics of a Bacteriophage, vB_Kox_ZX8, Isolated From ClinicalFrontiers in microbiology · 2021Article
- Bacteriophages ofJournal of medical microbiology · 2020Review
- Biological properties and genomics analysis of vB_KpnS_GH-K3, a Klebsiella phage with a putative depolymerase-like protein.Virus genes · 2019Article
- Bacteriophages in Natural and Artificial Environments.Pathogens (Basel, Switzerland) · 2019Review
- Genomic, morphological and functional characterisation of novel bacteriophage FNU1 capable of disrupting Fusobacterium nucleatum biofilms.Scientific reports · 2019Article
- Robust Approaches for the Production of Active Ingredient and Drug Product for Human Phage Therapy.Frontiers in microbiology · 2019Review
- Semi-Solid and Solid Dosage Forms for the Delivery of Phage Therapy to Epithelia.Pharmaceuticals (Basel, Switzerland) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo isolate and characterize bacteriophage lytic for the opportunistic pathogen Klebsiella oxytoca and their formulation into a range of solid dosage forms for in-vitro testing. METHODS AND
resultsWe report the isolation, genomic and functional characterization of a novel bacteriophage lytic for Klebsiella oxytoca, which does not infect the closely related Klebsiella pneumoniae. This bacteriophage was formulated into suppositories and troches and shown to be released and lyse underlying Klebsiella oxytoca bacteria in an in-vitro model. These bacteriophage formulations were stable for at least 49 days at 4°C.
conclusionsThe successful in-vitro assay of these formulations here suggests that they could potentially be tested in-vivo to determine whether such a therapeutic approach could modulate the gut microbiome, and control Klebsiella oxytoca overgrowth, during antibiotic therapy regimes. SIGNIFICANCE AND IMPACT OF THE STUDY: This study reports a novel bacteriophage specific for Klebsiella oxytoca which can be formulated into solid dosage forms appropriate for potential delivery in testing as a therapy to modulate gut microbiome during antibiotic therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.